RAC Regulatory Affairs Certification Exam — Questions and Answers

Question 1: What is the primary purpose of a Pre-Submission (Q-Sub) meeting with FDA?

To negotiate user fees for the application
To get FDA feedback on planned submissions or study designs before they are submitted (Correct answer)
To request expedited review of a pending application
To obtain binding approval before filing

Correct answer: To get FDA feedback on planned submissions or study designs before they are submitted

A Pre-Submission meeting allows sponsors to obtain FDA feedback on their planned approaches before formal submission, reducing uncertainty and improving submission quality.

Question 2: In a pediatric drug development program, what does a Pediatric Study Plan (PSP) require the sponsor to address?

Post-market surveillance commitments for adult populations
The IND safety reporting schedule for all age groups
The studies the sponsor plans to conduct in pediatric populations, relevant timelines, and justification for any waivers or deferrals (Correct answer)
Adult Phase 3 trial design and statistical power calculations

Correct answer: The studies the sponsor plans to conduct in pediatric populations, relevant timelines, and justification for any waivers or deferrals

A PSP outlines the sponsor's plan for studying the drug in relevant pediatric populations, including study designs, age groups, and justification for any requested waivers or deferrals under PREA.

Question 3: Which U.S. law established the FDA’s authority to oversee drug safety?

Prescription Drug Marketing Act
Drug Listing Act
Food, Drug, and Cosmetic Act (Correct answer)
Kefauver-Harris Amendment

Correct answer: Food, Drug, and Cosmetic Act

The Federal Food, Drug, and Cosmetic (FD&C) Act, passed in 1938, is the foundational law that granted the FDA its authority to regulate drugs, food, and cosmetics. It mandated that new drugs be proven safe before marketing and established requirements for labeling. While subsequent amendments like Kefauver-Harris added efficacy requirements, the FD&C Act initially established the FDA's core oversight of drug safety.

Question 4: An Institutional Review Board (IRB) is reviewing a protocol for a Phase 3 clinical trial. According to ICH GCP, which of the following is the PRIMARY responsibility of the IRB?

Confirming the sponsor has adequate financial resources to complete the study.
Protecting the rights, safety, and well-being of the human subjects participating in the trial. (Correct answer)
Verifying the accuracy of the data collected at the clinical sites.
Ensuring the scientific validity and statistical robustness of the trial design.

Correct answer: Protecting the rights, safety, and well-being of the human subjects participating in the trial.

The fundamental purpose of an IRB is to protect the rights and welfare of human research subjects. While scientific design is reviewed to assess the risk/benefit ratio, the IRB's primary mandate is the ethical oversight and protection of participants, not statistical validation, data verification, or financial auditing.

Question 5: Under 21 CFR Part 312, what is the maximum number of days FDA has to place a proposed IND on clinical hold after receiving the application?

15 days
60 days
45 days
30 days (Correct answer)

Correct answer: 30 days

FDA has 30 days to review a new IND and may place it on clinical hold within that period; if no hold is issued, the sponsor may proceed.

Question 6: A company seeks approval in both the EU and US simultaneously. The primary benefit of using the ICH CTD format is:

It eliminates the need for separate clinical trials in each region
It provides a harmonized submission structure accepted by both FDA and EMA (Correct answer)
It removes the requirement for region-specific labeling
It guarantees simultaneous approval timelines

Correct answer: It provides a harmonized submission structure accepted by both FDA and EMA

The ICH CTD (Common Technical Document) provides a standardized format accepted by FDA, EMA, and other ICH member agencies, reducing duplication in preparing dossiers.

Question 7: When building a regulatory strategy for a pediatric indication, which US regulatory requirement must be considered from early development?

FDA always grants automatic waivers for pediatric requirements in oncology
The Pediatric Research Equity Act (PREA) may require pediatric studies as part of the application (Correct answer)
Pediatric studies are voluntary and do not affect adult approval timelines
Pediatric studies are only required after adult approval is obtained

Correct answer: The Pediatric Research Equity Act (PREA) may require pediatric studies as part of the application

Under PREA, sponsors of new drugs and biologics for adult indications must assess the product in pediatric populations unless a waiver or deferral is granted.

Question 8: A company is planning global market entry for a Class II medical device. Which regulatory pathway typically offers the fastest US market access?

Humanitarian Device Exemption
De Novo classification
510(k) with predicate (Correct answer)
PMA

Correct answer: 510(k) with predicate

A 510(k) submission demonstrating substantial equivalence to a legally marketed predicate device is the fastest pathway for Class II devices.

Question 9: In a pharmacokinetics bridging study supporting a new pediatric formulation, which parameter is most critical to demonstrate bioequivalence to the adult reference product?

AUC and Cmax within the 80–125% confidence interval limits (Correct answer)
Renal clearance rate
Volume of distribution at steady state
Tmax

Correct answer: AUC and Cmax within the 80–125% confidence interval limits

FDA bioequivalence standards require the 90% CI for AUC and Cmax ratios to fall within 80–125% of the reference product.

Question 10: In GMP terms, what distinguishes a 'critical process parameter' (CPP) from a general process parameter?

CPPs are only monitored during validation, not routine production
CPPs require annual revalidation regardless of process changes
Variation in a CPP directly impacts a critical quality attribute of the product (Correct answer)
CPPs are defined by regulatory agencies, not manufacturers

Correct answer: Variation in a CPP directly impacts a critical quality attribute of the product

A CPP is one whose variability has a direct impact on a critical quality attribute (CQA), making it essential to monitor and control during manufacturing.

Question 11: Under the EU Medical Device Regulation (MDR 2017/745), which of the following BEST describes the purpose of the Post-Market Surveillance Report (PMSR)?

To fulfill marketing authorization requirements for the European Medicines Agency (EMA).
To provide a comprehensive summary of clinical investigation results for CE marking renewal.
To report all individual serious incidents to the competent authorities within 15 days.
To summarize the results and conclusions of post-market surveillance data analysis primarily for Class I devices. (Correct answer)

Correct answer: To summarize the results and conclusions of post-market surveillance data analysis primarily for Class I devices.

The PMSR, as defined in Article 85 of the EU MDR, is required for Class I devices. It is a summary of the results and conclusions of the analyses of the post-market surveillance data. For higher-risk devices (Class IIa, IIb, and III), a more comprehensive Periodic Safety Update Report (PSUR) is required.

Question 12: A pharmaceutical company becomes aware of new data confirming a causal link between its marketed drug and a previously unknown serious adverse reaction. To update the Prescribing Information to add a new warning, which is the MOST appropriate regulatory submission to the FDA?

An annual report.
A New Drug Application (NDA).
A "Changes Being Effected" (CBE-0) supplement. (Correct answer)
A Prior Approval Supplement (PAS).

Correct answer: A "Changes Being Effected" (CBE-0) supplement.

For critical safety-related labeling changes, such as adding or strengthening a contraindication, warning, precaution, or adverse reaction, regulations permit the submission of a "Changes Being Effected" (CBE-0) supplement. This allows the applicant to implement the change immediately upon the FDA's receipt of the supplement, ensuring rapid communication of important safety information. A PAS would require FDA approval before implementation, causing a delay.

Question 13: Which document formally establishes the acceptance criteria used to evaluate validation results?

Validation protocol (Correct answer)
Batch production record
Change control form
Standard operating procedure

Correct answer: Validation protocol

The validation protocol is written before execution and establishes the pre-approved acceptance criteria that results must meet.

Question 14: When developing a regulatory strategy, what is the primary purpose of pre-submission meetings and other formal interactions with health authorities?

To receive informal, non-binding feedback from competitors about the development plan.
To negotiate lower user fees for the marketing application review.
To obtain a binding guarantee of product approval before submitting the formal application.
To gain clarity on regulatory expectations, obtain guidance on the development plan, and de-risk the submission process. (Correct answer)

Correct answer: To gain clarity on regulatory expectations, obtain guidance on the development plan, and de-risk the submission process.

Formal interactions with health authorities, such as pre-submission meetings, are a critical component of regulatory strategy. Their main purpose is to allow sponsors to present their development plan and receive feedback, ask specific questions, and gain alignment on key issues before a formal marketing application is submitted. This proactive communication helps to identify and mitigate potential hurdles, clarify regulatory expectations, and ultimately reduce the risk of major delays or rejection during the review process.

Question 15: Under the Common Rule (45 CFR Part 46), which category of research qualifies for exemption from full IRB review?

Survey research involving adults where responses are recorded anonymously (Correct answer)
Research involving children in educational settings testing a new vaccine
Phase III clinical trials of marketed drugs
Research involving prisoners as subjects

Correct answer: Survey research involving adults where responses are recorded anonymously

Anonymous survey research involving adults falls under Common Rule Category 2 exemption when disclosure cannot reasonably place subjects at risk.

Question 16: A distributor receives a serious injury complaint for a device manufactured by a third party. Under 21 CFR Part 803, who bears the primary MDR reporting obligation?

The distributor, because they placed the product in commerce
Both the distributor and manufacturer equally
The device manufacturer (Correct answer)
The end user who experienced the injury

Correct answer: The device manufacturer

Under 21 CFR Part 803, manufacturers hold primary MDR reporting responsibility; distributors are required reporters only in specific circumstances defined in the regulation.

Question 17: According to U.S. FDA regulations for medical device labeling (21 CFR 801), which of the following is a required element on the label of a device intended for prescription use?

The Unique Device Identifier (UDI) in plain-text format only.
The reimbursement code for the device.
The statement "Caution: Federal law restricts this device to sale by or on the order of a physician" or the symbol "Rx Only". (Correct answer)
The date of the last FDA inspection of the manufacturing facility.

Correct answer: The statement "Caution: Federal law restricts this device to sale by or on the order of a physician" or the symbol "Rx Only".

21 CFR 801.109 specifies that a device restricted to use by or on the order of a licensed practitioner must bear either the full cautionary statement or the symbol "Rx Only" on its label. While the UDI is required on most device labels, it must be in both a human-readable (plain-text) and a machine-readable format. Reimbursement codes and inspection dates are not required label elements.

Question 18: Which GMP principle does the concept of 'cleaning validation' directly support?

Prevention of cross-contamination between products (Correct answer)
Equipment calibration frequency
Personnel qualification
Environmental monitoring accuracy

Correct answer: Prevention of cross-contamination between products

Cleaning validation demonstrates that cleaning procedures effectively remove product residues and prevent cross-contamination between successive batches or products.

Question 19: During a monitoring visit, a Clinical Research Associate (CRA) compares the data entered into the electronic Case Report Forms (eCRFs) with the original medical records and lab results. This process is known as:

Adverse Event Adjudication
Source Data Verification (SDV) (Correct answer)
Informed Consent Review
Protocol Amendment Submission

Correct answer: Source Data Verification (SDV)

Source Data Verification (SDV) is the process of checking the data transcribed into the Case Report Forms (CRFs) against the original source documents to ensure the data is accurate, complete, and verifiable.

Question 20: In the context of a Pre-NDA meeting (Type B meeting), what is the primary goal of the sponsor?

To align with FDA on the completeness of the NDA package and any outstanding issues before submission (Correct answer)
To negotiate post-market commitment requirements
To request accelerated approval based on surrogate endpoints
To obtain agreement on a Risk Evaluation and Mitigation Strategy (REMS)

Correct answer: To align with FDA on the completeness of the NDA package and any outstanding issues before submission

A Pre-NDA meeting allows sponsors to discuss the planned content and format of their submission to ensure FDA will accept it as a complete application.

Question 21: Which of the following records serves as the comprehensive 'recipe' or set of instructions for manufacturing a specific medical device, containing all procedures and specifications for a finished device?

Design History File (DHF)
Device History Record (DHR)
Device Master Record (DMR) (Correct answer)
Quality System Record (QSR)

Correct answer: Device Master Record (DMR)

The Device Master Record (DMR), as defined in 21 CFR 820, is a compilation of records containing the procedures and specifications for a finished device. It includes device specifications, production process specifications, quality assurance procedures, and packaging and labeling specifications. The DHF describes the design history, and the DHR provides evidence that a specific batch was made according to the DMR.

Question 22: Which of the following activities is the BEST example of proactive post-market surveillance?

Investigating a customer complaint about a device failure.
Submitting a vigilance report to a competent authority after a serious injury.
Conducting a customer survey to gather data on device usability and performance in a real-world setting. (Correct answer)
Issuing a field safety corrective action to address a known product defect.

Correct answer: Conducting a customer survey to gather data on device usability and performance in a real-world setting.

Proactive post-market surveillance involves activities initiated by the manufacturer to actively search for information about a device's performance, rather than waiting for events to be reported. A customer survey is a method of actively seeking out this information. Investigating complaints, submitting vigilance reports, and issuing corrections are all reactive measures taken in response to an identified issue or event.

Question 23: Which of the following best describes a 'regulatory gap analysis' in strategic planning?

Evaluating FDA inspection gaps in manufacturing sites
Assessing current dossier status against requirements for target markets (Correct answer)
Comparing competitor regulatory filings to identify opportunities
Identifying missing clinical data in published literature

Correct answer: Assessing current dossier status against requirements for target markets

A regulatory gap analysis compares the existing data package against the submission requirements for target regulatory agencies to identify what additional work is needed.

Question 24: Which form is submitted to the FDA to report an adverse drug event?

Form FDA 1571
Form FDA 356h
Form 483
Form FDA 3500 (Correct answer)

Correct answer: Form FDA 3500

Form FDA 3500, also known as the MedWatch Voluntary Reporting Form, is the primary form used by healthcare professionals and consumers to report serious adverse events, product problems, or quality issues with medical products. This includes drugs, biologics, and medical devices. It is essential for the FDA's pharmacovigilance efforts to monitor product safety once on the market.

Question 25: A medical device company is preparing a premarket submission for a new Class II diagnostic device. The device has the same intended use and similar technological characteristics as a legally marketed device (a predicate device). Which type of submission is MOST appropriate to seek marketing authorization in the United States?

Premarket Notification (510(k)) (Correct answer)
Premarket Approval (PMA)
De Novo Classification Request
Investigational Device Exemption (IDE)

Correct answer: Premarket Notification (510(k))

A Premarket Notification (510(k)) is the appropriate submission pathway for a device that is substantially equivalent to a legally marketed predicate device. This pathway is used for most Class II devices and some Class I devices. The submission's purpose is to demonstrate that the new device is as safe and effective as the predicate.

Question 26: What is the primary regulatory concern addressed by 21 CFR Part 11?

Environmental controls in cleanrooms
Data backup and disaster recovery
Computer system validation protocols
Electronic records and electronic signatures (Correct answer)

Correct answer: Electronic records and electronic signatures

21 CFR Part 11 establishes criteria under which FDA considers electronic records and electronic signatures to be trustworthy and equivalent to paper records.

Question 27: When preparing a briefing package for a Pre-Submission (Q-Sub) meeting with the FDA for a new medical device, which of the following is the MOST critical component to include?

A complete list of all anticipated marketing claims.
Detailed financial projections for the first five years.
Specific, forward-looking questions for the agency on which feedback is sought. (Correct answer)
The final, locked-down version of the device's Instructions for Use (IFU).

Correct answer: Specific, forward-looking questions for the agency on which feedback is sought.

The primary purpose of a Q-Submission is to obtain feedback from the agency to guide product development and submission preparation. Therefore, including clear, specific, and well-reasoned questions is the most critical component, as these questions will frame the entire discussion and the feedback provided by the FDA. The other elements, while potentially part of the overall package, are secondary to the core goal of getting answers to specific regulatory, technical, or clinical questions.

Question 28: During an FDA inspection, an investigator asks to see the records demonstrating that a specific lot of a finished device was manufactured in accordance with its approved specifications. Which of the following documents should the manufacturer provide?

The Device History Record (DHR) (Correct answer)
The Device Master Record (DMR)
The Design History File (DHF)
The Quality System Audit reports

Correct answer: The Device History Record (DHR)

The Device History Record (DHR), as required by 21 CFR 820.184, contains the production history for a specific batch, lot, or unit. It includes dates of manufacture, quantity manufactured, and acceptance records demonstrating the device was produced in accordance with the Device Master Record (DMR).

Question 29: Under the Biosimilar pathway (351(k) of the PHS Act), what must an applicant demonstrate beyond showing no clinically meaningful differences from the reference product?

That the biosimilar is manufactured at the same facility as the reference product
That the reference product's patent has expired before filing
Biosimilarity based on analytical, nonclinical, and clinical data, and optionally 'interchangeability' requiring additional switching study data (Correct answer)
That the biosimilar has the exact same amino acid sequence as the reference biological product

Correct answer: Biosimilarity based on analytical, nonclinical, and clinical data, and optionally 'interchangeability' requiring additional switching study data

Biosimilar applicants must demonstrate biosimilarity through a totality-of-evidence approach; the higher standard of 'interchangeability' requires additional switching studies showing no diminished safety or efficacy.

Question 30: A company is creating a global regulatory strategy for a new Class II medical device. Which of the following activities is essential to perform during the earliest stages of strategic planning?

Conducting a comprehensive gap analysis of the technical documentation against the requirements of all target markets.
Identifying and defining the device's intended use and target patient population. (Correct answer)
Translating the full user manual into the languages of all potential markets.
Finalizing the marketing and promotional materials for all target countries.

Correct answer: Identifying and defining the device's intended use and target patient population.

The foundational step in any global regulatory strategy is to clearly define the device, which includes its intended use and target population. This information is critical as it directly influences the device's classification, the selection of appropriate regulatory pathways in different markets, and the scope of required clinical evidence. All subsequent strategic decisions build upon this initial definition.

Question 31: A strategic decision to seek 'rolling review' in the US allows a sponsor to:

Submit completed sections of the NDA/BLA for review as they are finished, before the full dossier is complete (Correct answer)
Bypass standard review timelines for any serious disease
Submit directly to the FDA Commissioner, bypassing the review division
Submit manufacturing sections before clinical sections are complete

Correct answer: Submit completed sections of the NDA/BLA for review as they are finished, before the full dossier is complete

Rolling review allows sponsors with Fast Track designation to submit completed NDA/BLA modules for FDA review on a rolling basis rather than waiting until the entire application is complete.

Question 32: A pharmaceutical manufacturer receives a batch of active pharmaceutical ingredient that fails identity testing. What is the required disposition?

Retest using a different method before rejecting
Use under a deviation if potency is acceptable
Reject and return or destroy the material (Correct answer)
Place in quarantine and notify the supplier only

Correct answer: Reject and return or destroy the material

Under 21 CFR 211.84, components failing identity testing must be rejected and cannot be used in drug product manufacturing.

Question 33: A company modifies its previously cleared 510(k) device. The change involves a minor alteration to the user interface software that does not affect the device's intended use, fundamental scientific technology, or safety and effectiveness. Which of the following is the most appropriate course of action?

Submit a De Novo request for the modified device.
Document the change in the Design History File and assess if a new 510(k) is needed. (Correct answer)
Submit a new Premarket Approval (PMA) application.
Immediately recall the product from the market.

Correct answer: Document the change in the Design History File and assess if a new 510(k) is needed.

For modifications to a 510(k)-cleared device, the manufacturer must assess whether the change could significantly affect the safety or effectiveness of the device. If the change is minor and does not trigger this threshold, a new 510(k) may not be required. The proper procedure is to document the change and the justification for not submitting a new 510(k) in the quality system records, such as the Design History File, per 21 CFR 820.

Question 34: What is the significance of a 'retrospective validation' approach?

It validates analytical testing methods
It validates a process before production begins
It uses historical production data to validate an established process (Correct answer)
It concurrently collects data during routine production

Correct answer: It uses historical production data to validate an established process

Retrospective validation uses accumulated historical batch data to demonstrate that an existing process has been operating in a state of control.

Question 35: A manufacturer becomes aware that a series of malfunctions with its infusion pump necessitates a nationwide field correction to prevent an unreasonable risk of substantial public harm. The company also has information reasonably suggesting these malfunctions may have contributed to a patient's death. According to 21 CFR 803, what is the mandatory reporting timeframe to the FDA for this event?

10 working days after initiating the field correction.
5 working days after becoming aware that a reportable event requires remedial action. (Correct answer)
Within 24 hours via a phone call to the district office.
30 calendar days after becoming aware of the event.

Correct answer: 5 working days after becoming aware that a reportable event requires remedial action.

According to 21 CFR 803.53, a manufacturer must submit a 5-day report if they become aware that a reportable event necessitates remedial action to prevent an unreasonable risk of substantial harm to the public health. The need for a nationwide field correction to prevent such harm triggers this expedited reporting requirement.

Question 36: Which of the following best describes the role of an FDA Advisory Committee in the product approval process?

To provide a final, legally binding decision on the approvability of a product.
To conduct its own independent audits of the sponsor's clinical trial data.
To provide independent, expert advice and recommendations to the FDA, which the agency considers in its final decision. (Correct answer)
To negotiate labeling and post-marketing commitments directly with the sponsor.

Correct answer: To provide independent, expert advice and recommendations to the FDA, which the agency considers in its final decision.

FDA Advisory Committees are panels of external experts who provide non-binding scientific and medical advice to the agency. The FDA makes the final decision on product approval but gives significant weight to the committee's recommendations. The committee's role is purely advisory; it does not make binding decisions or negotiate directly with sponsors.

Question 37: A medical device company is finalizing the development of a new infusion pump. Which of the following activities BEST satisfies the requirement for Design Validation under 21 CFR 820.30(g)?

Conducting performance testing on the pump's motor to confirm it meets torque specifications.
Performing software unit testing to ensure all code modules function as specified.
Simulating clinical use with intended users in a controlled environment to confirm user needs are met. (Correct answer)
Compiling the Device Master Record (DMR) to ensure all specifications are documented.

Correct answer: Simulating clinical use with intended users in a controlled environment to confirm user needs are met.

Design validation's purpose is to ensure the finished device conforms to defined user needs and intended uses under actual or simulated use conditions. Simulating clinical use with actual users directly tests this. Software unit testing and motor performance testing are examples of design *verification*—confirming the design output meets the design input specifications. Compiling the DMR is a documentation activity.

Question 38: A strategic regulatory plan should include contingency scenarios primarily because:

They eliminate the need for additional pre-submission meetings
Regulators require contingency plans as part of every submission
Contingency plans reduce the cost of manufacturing scale-up
Unexpected agency feedback, clinical failures, or policy changes can derail timelines without alternatives ready (Correct answer)

Correct answer: Unexpected agency feedback, clinical failures, or policy changes can derail timelines without alternatives ready

Contingency planning prepares teams to respond quickly to regulatory setbacks, clinical surprises, or guideline changes without losing critical development time.

Question 39: A company plans to use a validated biomarker as a primary endpoint in a Phase II trial to support dose selection. What FDA pathway provides formal endorsement of this biomarker's use?

Biomarker Qualification Program (Correct answer)
Accelerated Approval pathway
Breakthrough Therapy designation
Fast Track designation

Correct answer: Biomarker Qualification Program

FDA's Biomarker Qualification Program formally evaluates and endorses a biomarker for a specific context of use in drug development.

Question 40: Under the EU regulatory framework, which procedure allows a centralized single application valid across all EU member states?

Centralized Procedure (CP) via EMA (Correct answer)
Decentralized Procedure (DCP)
Mutual Recognition Procedure (MRP)
National Procedure in the reference member state

Correct answer: Centralized Procedure (CP) via EMA

The Centralized Procedure through EMA results in a single marketing authorization valid across all EU/EEA member states, making it strategically advantageous for broad EU access.

Question 41: Which internal department is most often engaged during regulatory planning?

Clinical and R&D teams (Correct answer)
Human Resources
Logistics
Finance

Correct answer: Clinical and R&D teams

During regulatory planning, the regulatory affairs department works most closely with clinical and R&D teams because these departments generate the scientific data required for regulatory submissions. Regulatory professionals guide these teams on study design, data collection, and documentation to ensure compliance with regulatory standards. This collaboration is essential for developing a robust regulatory strategy and preparing comprehensive dossiers.

Question 42: In regulatory strategic planning, a 'target product profile' (TPP) serves as:

A post-approval document describing approved indications
A regulatory requirement submitted to FDA at IND stage
A marketing document describing competitive positioning
A prospective summary of the desired characteristics of a product that guides development decisions (Correct answer)

Correct answer: A prospective summary of the desired characteristics of a product that guides development decisions

The TPP is a prospective, dynamic document that articulates the intended clinical profile of the product and serves as a benchmark to align development and regulatory strategy.

Question 43: Which FDA database is the PRIMARY source manufacturers must search when evaluating complaints for potential MDR reportability?

FDA FAERS (Adverse Event Reporting System)
FDA 510(k) Premarket Notification database
DailyMed
MAUDE (Manufacturer and User Facility Device Experience) (Correct answer)

Correct answer: MAUDE (Manufacturer and User Facility Device Experience)

MAUDE contains MDRs submitted by manufacturers, importers, and device facilities, making it the primary reference for evaluating complaint trends and MDR precedents.

Question 44: Which strategy is MOST appropriate when a company seeks regulatory approval in multiple markets with very different data requirements?

Submit only to markets with the most relaxed requirements first, then adapt
Use a single country's approval to leverage automatic recognition in all other markets
Develop a separate, fully independent dossier for each market from scratch
Build a core global dossier that meets the most stringent requirements, with market-specific modules appended (Correct answer)

Correct answer: Build a core global dossier that meets the most stringent requirements, with market-specific modules appended

Building a core global dossier to the highest standard (often ICH CTD format) with modular regional additions is the most efficient multi-market strategy, reducing duplication and inconsistency.

Question 45: In a Phase I dose-escalation oncology trial, what is the primary endpoint typically used to determine the Maximum Tolerated Dose (MTD)?

Overall survival
Tumor response rate
Dose-Limiting Toxicity (DLT) (Correct answer)
Pharmacokinetic AUC

Correct answer: Dose-Limiting Toxicity (DLT)

DLTs observed during the first treatment cycle define the MTD boundary in classic 3+3 and modified dose-escalation designs.

Question 46: Under ISO 13485:2016, which clause specifically requires procedures for post-market surveillance activities including feedback and complaint handling?

Clause 6.2 — Human Resources
Clause 8.2 — Monitoring and Measurement (Correct answer)
Clause 7.4 — Purchasing
Clause 4.1 — General Requirements

Correct answer: Clause 8.2 — Monitoring and Measurement

ISO 13485:2016 Clause 8.2 covers monitoring and measurement, including customer feedback, complaint handling, and reporting to regulatory authorities.

Question 47: A sponsor modifies the protocol to add a new secondary endpoint mid-trial without prior IRB approval. This action most directly violates which regulation?

21 CFR 312.62
21 CFR 314.50
21 CFR 50.27
21 CFR 56.108 (Correct answer)

Correct answer: 21 CFR 56.108

21 CFR 56.108 requires IRB review and approval of protocol amendments before implementation, including changes to study endpoints.

Question 48: Which regulatory document is used to gain permission to ship a drug across state lines before approval?

Biologics License Application
New Drug Application (NDA)
ANDA
Investigational New Drug (IND) (Correct answer)

Correct answer: Investigational New Drug (IND)

An Investigational New Drug (IND) application is the regulatory document submitted to the FDA to obtain permission to conduct clinical trials in humans. This approval allows the sponsor to ship the investigational drug across state lines for the purpose of these clinical investigations. Without an approved IND, interstate commerce of an unapproved drug for human testing is prohibited.

Question 49: What is the primary goal of Phase 1 clinical trials?

Gather long-term outcome data
Compare efficacy with existing drugs
Assess safety and dosing (Correct answer)
Evaluate marketing strategies

Correct answer: Assess safety and dosing

Phase 1 clinical trials are the first stage of testing a new drug in humans, typically involving a small group of healthy volunteers or patients with the target condition. The primary goal is to assess the drug's safety, determine a safe dosage range, and understand how the drug is metabolized and excreted (pharmacokinetics). Efficacy is not the main focus at this early stage.

Question 50: Which element is MANDATORY in a PMS plan according to EU MDR Annex III?

A proactive and systematic procedure to collect and review post-market experience (Correct answer)
A list of countries where the device is not yet marketed
A schedule of notified body surveillance audits
A marketing communication plan for healthcare providers

Correct answer: A proactive and systematic procedure to collect and review post-market experience

EU MDR Annex III requires the PMS plan to specify a proactive, systematic procedure for gathering and reviewing post-market experience from clinical and non-clinical sources.

Question 51: Which regulatory pathway expedites the review of drugs for serious conditions in the U.S.?

Hatch-Waxman Act
ANDA
Orphan Drug Act
Fast Track designation (Correct answer)

Correct answer: Fast Track designation

Fast Track designation is an FDA program designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. This designation allows for more frequent communication with the FDA and, potentially, a rolling review of the application, aiming to get important new drugs to patients sooner.

Question 52: Why is strategic planning important in regulatory affairs?

To align regulatory goals with company strategy (Correct answer)
To avoid documentation
To increase manufacturing speed
To bypass regulatory reviews

Correct answer: To align regulatory goals with company strategy

Strategic planning in regulatory affairs is crucial for integrating regulatory requirements and timelines into the overall business objectives of a company. It ensures that product development, market entry, and lifecycle management are conducted in a way that is compliant, efficient, and supports the company's commercial goals. This alignment helps avoid delays, optimize resource allocation, and achieve successful market access.

Question 53: Which regulatory strategy element addresses how a company will respond if FDA issues a Complete Response Letter (CRL)?

Risk communication plan
The pharmacovigilance system master file
The regulatory intelligence database
Resubmission and response strategy in the contingency plan (Correct answer)

Correct answer: Resubmission and response strategy in the contingency plan

A resubmission and response strategy within the contingency plan defines timelines, resources, and decision criteria for addressing a CRL to minimize approval delays.

Question 54: Which of the following best describes the concept of 'state of the art' as applied to post-market surveillance under EU MDR?

The most expensive manufacturing technique available
The device with the highest unit sales volume in the market
The current best available technology, clinical evidence, and regulatory guidance relevant to the device (Correct answer)
The original design specification submitted at time of certification

Correct answer: The current best available technology, clinical evidence, and regulatory guidance relevant to the device

Under EU MDR, 'state of the art' encompasses the best current knowledge in technology, clinical evidence, and safety standards, and PMS must benchmark performance against it.

Question 55: When building a regulatory strategy for a biosimilar product in the US, which reference product data source is MOST important to characterize during planning?

The FDA's prior approval history for other biosimilars in the class
The reference listed drug's (RLD) approved labeling, clinical pharmacology, and safety database (Correct answer)
The manufacturing site master file of the reference product
The innovator's patent expiry timeline

Correct answer: The reference listed drug's (RLD) approved labeling, clinical pharmacology, and safety database

Biosimilar development strategy centers on demonstrating no clinically meaningful differences from the RLD, making the RLD's labeling, PK/PD profile, and safety data foundational inputs.

Question 56: What is the strategic advantage of using a pre-submission meeting (Type B meeting) with FDA during drug development?

It guarantees expedited review timelines post-submission
It allows sponsors to align on study designs, endpoints, and data requirements before costly investments (Correct answer)
It locks FDA into approving the submission without further review
It substitutes for formal Phase 2 clinical trial requirements

Correct answer: It allows sponsors to align on study designs, endpoints, and data requirements before costly investments

Type B meetings (including End-of-Phase 2 and pre-NDA meetings) allow sponsors to gain FDA feedback on development plans before committing resources, reducing submission risk.

Question 57: Which regulatory strategy is most appropriate when a company needs to launch a product simultaneously in the US, EU, and Japan?

Prioritizing the largest market first before others
Sequential submissions to each region independently
Delegating each region to separate uncoordinated teams
Global regulatory harmonization strategy using ICH guidelines (Correct answer)

Correct answer: Global regulatory harmonization strategy using ICH guidelines

A global harmonization strategy leveraging ICH guidelines enables concurrent submissions across regions by aligning data packages to shared standards.

Question 58: Which statement correctly describes the relationship between GMP and validation?

Validation replaces the need for in-process testing during routine manufacturing
Validation provides documented evidence that GMP processes consistently produce acceptable results (Correct answer)
Validation activities are optional if process analytical technology is used
GMP requires validation only for sterile products

Correct answer: Validation provides documented evidence that GMP processes consistently produce acceptable results

Validation provides the documented scientific evidence that GMP processes, equipment, and systems consistently produce outcomes meeting predetermined specifications.

Question 59: Under FDA's Pediatric Research Equity Act (PREA), when must a sponsor submit a Pediatric Study Plan (PSP)?

No later than 60 days after an end-of-Phase II meeting (Correct answer)
Before initiating any Phase I trial
With the NDA/BLA submission
At IND submission

Correct answer: No later than 60 days after an end-of-Phase II meeting

PREA requires sponsors to submit an initial PSP (iPSP) no later than 60 days after the end-of-Phase II meeting with FDA.

Question 60: In the context of PMS complaint handling, what does 'MDR decisioning' require the manufacturer to document?

Marketing strategy changes resulting from the complaint
The rationale for why a complaint does or does not meet MDR reporting criteria (Correct answer)
The customer's satisfaction score after complaint resolution
The number of social media reposts of the complaint

Correct answer: The rationale for why a complaint does or does not meet MDR reporting criteria

FDA expects written documentation of the analysis and justification used to determine whether each complaint meets MDR reportability thresholds.

Question 61: Which tool is most useful for proactively identifying regulatory risks before a product submission?

Post-market surveillance data review
FMEA (Failure Mode and Effects Analysis) of the regulatory strategy (Correct answer)
A Gantt chart of submission milestones
SWOT analysis applied to regulatory activities

Correct answer: FMEA (Failure Mode and Effects Analysis) of the regulatory strategy

FMEA applied to regulatory strategy systematically identifies potential failure modes in the regulatory plan and their impact on approval timelines.

Question 62: A medical device manufacturer identifies a software anomaly in its patient monitoring system that may, in rare circumstances, cause a temporary, 5-second data lag. This could theoretically lead to a brief delay in clinical intervention. The manufacturer initiates a voluntary correction. How would the FDA MOST likely classify this recall?

Market Withdrawal
Class I
Class III
Class II (Correct answer)

Correct answer: Class II

A Class II recall applies to situations where the use of a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The scenario describes a potential for temporary harm (delay in intervention), but serious harm is not a reasonable probability, fitting the Class II definition.

Question 63: What distinguishes a 'specification' from a 'standard' in pharmaceutical quality systems?

Specifications require FDA approval while standards do not
Standards are company-specific while specifications are industry-wide
Specifications are optional while standards are mandatory
A specification defines acceptance criteria for a material or product, while a standard is a reference document providing broader guidance (Correct answer)

Correct answer: A specification defines acceptance criteria for a material or product, while a standard is a reference document providing broader guidance

A specification defines the acceptance criteria a material or product must meet, whereas a standard is typically a reference document or compendial monograph providing broader technical guidance.

Question 64: What is the purpose of a Data Safety Monitoring Board (DSMB) in a Phase III clinical trial?

To provide independent interim safety and efficacy reviews and recommend trial continuation, modification, or stopping (Correct answer)
To adjudicate adverse event causality for IND safety reports
To approve protocol amendments on behalf of the FDA
To replace the IRB for ongoing safety oversight

Correct answer: To provide independent interim safety and efficacy reviews and recommend trial continuation, modification, or stopping

A DSMB independently reviews unblinded interim data to protect subject safety, ensure data integrity, and advise the sponsor on trial continuation.

Question 65: Which of the following best describes the concept of 'mutual recognition' in the EU regulatory system?

A procedure where one member state's marketing authorization is recognized and extended to other member states (Correct answer)
A process by which CHMP reviews all national authorizations
A reciprocal agreement between the EU and US to share safety data
All EU countries must accept EMA-approved products without review

Correct answer: A procedure where one member state's marketing authorization is recognized and extended to other member states

The Mutual Recognition Procedure (MRP) allows a marketing authorization granted by one EU Reference Member State to be recognized and extended to other Concerned Member States.

Question 66: During a scheduled management review, the Head of Quality presents data showing a negative trend in supplier performance, specifically an increase in late deliveries of a critical component. According to the Quality System Regulation (21 CFR 820.20), what is the MOST appropriate output of this review?

An assignment of an action item to investigate the supplier issue and a commitment of resources to address it. (Correct answer)
A directive to the purchasing department to immediately find a new supplier.
A note in the meeting minutes to re-evaluate the trend at the next quarterly review.
A decision to increase the safety stock of the critical component to buffer against late deliveries.

Correct answer: An assignment of an action item to investigate the supplier issue and a commitment of resources to address it.

Management review, as defined in 21 CFR 820.20(c), requires reviewing the suitability and effectiveness of the quality system and making decisions or assigning actions where needed. The primary role of management is to assess data and assign actions and resources to ensure the effectiveness of the quality system. Simply finding a new supplier is premature, increasing stock is a temporary fix, and waiting is not proactive.

Question 67: What does the term 'qualification' refer to in the context of GMP equipment validation?

Demonstrating that equipment is properly installed, operates correctly, and performs as intended (Correct answer)
Confirming that suppliers meet quality standards
Documenting that a process consistently produces a product meeting specifications
Verifying that analytical methods are suitable for their intended use

Correct answer: Demonstrating that equipment is properly installed, operates correctly, and performs as intended

Equipment qualification (IQ/OQ/PQ) demonstrates that equipment is installed correctly, operates as designed, and performs consistently within specified parameters.

Question 68: In strategic regulatory planning, 'regulatory intelligence' refers to:

AI-based tools that predict approval dates
Competitive intelligence on rival companies' pipelines
Background checks on agency reviewers
Systematic monitoring of agency guidance, decisions, and policy trends to inform strategy (Correct answer)

Correct answer: Systematic monitoring of agency guidance, decisions, and policy trends to inform strategy

Regulatory intelligence involves tracking agency guidance documents, precedent decisions, policy shifts, and advisory committee trends to proactively shape development strategy.

Question 69: Under 21 CFR 314.50, what is required to be included in the 'Summary' section (Module 2) of an NDA?

Financial disclosure forms for all clinical investigators
Comprehensive summaries of quality, nonclinical, and clinical data including an integrated benefit-risk assessment (Correct answer)
Only the proposed prescribing information and labeling
Raw clinical data tabulations and case report forms

Correct answer: Comprehensive summaries of quality, nonclinical, and clinical data including an integrated benefit-risk assessment

Module 2 of the CTD/NDA requires structured summaries of quality, nonclinical, and clinical data, culminating in an integrated benefit-risk discussion.

Question 70: What is the primary function of a Design History File (DHF) in the development of a medical device subject to 21 CFR Part 820?

It documents the clinical trial endpoints and protocol amendments for the device
It serves as the Device Master Record for manufacturing instructions
It contains the records describing the design history of a finished device, demonstrating that the design was developed in accordance with the approved design plan (Correct answer)
It is FDA's internal review record generated during the 510(k) premarket review

Correct answer: It contains the records describing the design history of a finished device, demonstrating that the design was developed in accordance with the approved design plan

The DHF compiles all design control records for a device, providing objective evidence that the design development process met requirements under 21 CFR 820.30.

Question 71: What role does regulatory intelligence play in strategic planning?

Prepares advertising slogans
Eliminates need for marketing
Replaces submission documents
Informs proactive decision-making (Correct answer)

Correct answer: Informs proactive decision-making

Regulatory intelligence involves systematically collecting, analyzing, and interpreting information about current and emerging regulatory requirements, guidelines, and trends worldwide. This intelligence allows companies to anticipate future regulatory challenges, adapt their development strategies, and make proactive decisions. It helps in navigating complex global regulatory landscapes and optimizing product development pathways.

Question 72: Which FDA meeting type is categorized as 'Type B' for drug development?

Meetings requested to discuss labeling post-approval
Meetings to resolve manufacturing disputes
Post-market surveillance planning meetings
End-of-Phase 2 meetings and pre-NDA/BLA meetings (Correct answer)

Correct answer: End-of-Phase 2 meetings and pre-NDA/BLA meetings

Type B meetings include End-of-Phase 2 (EOP2) and pre-NDA/BLA meetings, which are critical milestones in drug development requiring FDA input.

Question 73: What is a key feature of effective regulatory communication?

Relying solely on emails
Communicating only after rejection
Using technical jargon
Clear, accurate, and timely dialogue (Correct answer)

Correct answer: Clear, accurate, and timely dialogue

Effective regulatory communication is characterized by clear, accurate, and timely dialogue with regulatory authorities. This approach fosters transparency, builds trust, and facilitates efficient review processes. Proactive and precise communication helps address questions promptly, clarify complex issues, and avoid misunderstandings that could lead to delays or rejections.

Question 74: In a GMP environment, which out-of-specification (OOS) investigation step must occur before retesting?

CAPA implementation
Batch disposition decision
Phase I laboratory investigation (Correct answer)
Regulatory notification

Correct answer: Phase I laboratory investigation

FDA's 2006 OOS guidance requires a Phase I laboratory investigation to assess analyst error and instrument performance before any retesting.

Question 75: A medical device manufacturer discovers a recurring nonconformity during in-process testing of a Class II device. According to 21 CFR 820.100, which of the following is the MOST appropriate initial step in the Corrective and Preventive Action (CAPA) process?

Analyzing all relevant quality data to identify the root cause of the nonconformity. (Correct answer)
Disseminating information about the quality problem to all production staff.
Implementing a production-wide change to the manufacturing process.
Immediately scrapping all affected lots of the device.

Correct answer: Analyzing all relevant quality data to identify the root cause of the nonconformity.

According to 21 CFR 820.100(a), the CAPA process requires manufacturers to establish procedures for analyzing various sources of quality data to identify existing and potential causes of nonconforming product. Investigating the cause of the nonconformity is a critical first step before implementing any corrective actions, ensuring that the action taken is effective and appropriate.

Question 76: When FDA issues an 'Additional Information' (AI) request during a 510(k) review, what happens to the review clock?

FDA has 45 days to review the response
It continues running uninterrupted
It is suspended until the sponsor responds (Correct answer)
It resets to day 1

Correct answer: It is suspended until the sponsor responds

The review clock is placed on hold (suspended) while FDA awaits the sponsor's response to an AI request.

Question 77: Under 21 CFR 820.30, Design Controls are required for which of the following categories of medical devices?

All Class II, Class III, and certain specified Class I devices. (Correct answer)
Class II and Class III devices only.
All Class I devices.
All Class I, II, and III devices.

Correct answer: All Class II, Class III, and certain specified Class I devices.

21 CFR 820.30(a) specifies that design controls apply to all Class II and Class III medical devices. It also applies to a specific list of Class I devices, such as those automated with computer software and surgeon's gloves. Therefore, not all Class I devices are subject to design controls.

Question 78: Which FDA guidance describes the expectation that manufacturers maintain a vigilance system to detect, report, and correct problems with marketed devices?

FDA Guidance on Predetermined Change Control Plans
FDA Guidance on Q-Submissions
FDA Guidance on De Novo Classification
FDA Guidance on Medical Device Reporting for Manufacturers (Correct answer)

Correct answer: FDA Guidance on Medical Device Reporting for Manufacturers

FDA's MDR guidance for manufacturers outlines the vigilance system expectations, including what constitutes a reportable event and required timelines.

Question 79: Which document outlines a company's regulatory submission strategy?

Clinical trial protocol
Advertising budget
Manufacturing plan
Regulatory strategy plan (Correct answer)

Correct answer: Regulatory strategy plan

A regulatory strategy plan is a comprehensive document that outlines the specific regulatory pathway, key milestones, timelines, and resources needed to bring a product to market and maintain its compliance throughout its lifecycle. It details how the company will navigate regulatory requirements, manage submissions, and interact with health authorities. This plan serves as a roadmap for all regulatory activities.

Question 80: In regulatory strategic planning for a new molecular entity (NME), the end-of-Phase 2 (EOP2) meeting is critical primarily because:

It finalizes the product label language
FDA approval is granted at this meeting if Phase 2 data are positive
It aligns the Phase 3 program design with FDA's requirements before committing major resources (Correct answer)
It triggers automatic Priority Review designation

Correct answer: It aligns the Phase 3 program design with FDA's requirements before committing major resources

The EOP2 meeting allows sponsors to confirm that Phase 3 design, endpoints, and statistical approach meet FDA's requirements before investing in expensive pivotal trials.

Question 81: What is the maximum review period FDA targets for a Traditional 510(k) under MDUFA commitments?

60 calendar days
90 calendar days (Correct answer)
180 calendar days
30 calendar days

Correct answer: 90 calendar days

FDA's MDUFA performance goal for Traditional 510(k) review is 90 calendar days from receipt.

Question 82: Which concept does ICH Q9 Quality Risk Management introduce as a foundation for risk-based decision-making?

Risk assessment, risk control, and risk review (Correct answer)
Quality by design principles
Design space and proven acceptable ranges
Continual process verification

Correct answer: Risk assessment, risk control, and risk review

ICH Q9 establishes risk assessment, risk control, and risk review as the core elements of a structured quality risk management process.

Question 83: A biologics manufacturer files a Biologics License Application (BLA). Under which regulatory authority is a BLA reviewed, as distinct from an NDA?

Section 505 of the FD&C Act
Section 351 of the Public Health Service (PHS) Act (Correct answer)
Section 515 of the FD&C Act
Section 510(k) of the FD&C Act

Correct answer: Section 351 of the Public Health Service (PHS) Act

BLAs for biological products are regulated under Section 351 of the Public Health Service Act, while NDAs are regulated under Section 505 of the FD&C Act.

Question 84: Which GMP regulation governs Current Good Manufacturing Practice for finished pharmaceuticals in the US?

21 CFR Part 110
21 CFR Part 600
21 CFR Part 211 (Correct answer)
21 CFR Part 820

Correct answer: 21 CFR Part 211

21 CFR Part 211 establishes CGMP requirements for finished pharmaceutical products manufactured in the US.

Question 85: A sponsor seeks to enroll a pregnant woman in a Phase II trial of a new antiviral. Under 21 CFR Part 50 Subpart B, this population is classified as:

An exempt population if consent is obtained from the father
A vulnerable subject requiring additional safeguards (Correct answer)
A non-regulated population if the condition is life-threatening
An excluded population under all circumstances

Correct answer: A vulnerable subject requiring additional safeguards

Pregnant women are a vulnerable population under 45 CFR Part 46 Subpart B, requiring additional protections and specific risk-benefit criteria.

Question 86: A regulatory team is evaluating whether to seek Breakthrough Therapy Designation. What is the key eligibility criterion?

The drug must treat a rare disease affecting fewer than 200,000 patients
Preliminary clinical evidence must show substantial improvement over available therapies for a serious condition (Correct answer)
Phase 3 trials must be completed with positive results
The product must already have FDA Fast Track status

Correct answer: Preliminary clinical evidence must show substantial improvement over available therapies for a serious condition

Breakthrough Therapy Designation requires preliminary clinical evidence showing substantial improvement on a clinically meaningful endpoint over existing therapies for a serious condition.

Question 87: In a global regulatory strategy, which factor most significantly influences the sequence of country submissions?

Always submit to FDA first as other agencies follow its decisions
Commercial opportunity, unmet medical need, and regulatory complexity in each market (Correct answer)
Alphabetical order of country names
The country where the product was invented

Correct answer: Commercial opportunity, unmet medical need, and regulatory complexity in each market

Submission sequence is strategically determined by factors including market potential, patient access urgency, regulatory precedent-setting value, and agency workload.

Question 88: What term describes the process by which an IRB reviews a study where the only involvement is a minimal-risk survey of adults?

Full board review
Exempt determination (Correct answer)
Expedited review
Waived consent review

Correct answer: Exempt determination

Research involving minimal risk with anonymous surveys of adults may qualify as exempt from IRB oversight under 45 CFR 46.104.

Question 89: Which action is required when a manufacturer's PMS data shows that a device's benefit-risk profile is no longer acceptable?

Conduct an internal meeting only, with no external notification
Transfer responsibility to the distributor
Increase marketing efforts to shift perception of the device
Initiate a field safety corrective action and notify relevant competent authorities (Correct answer)

Correct answer: Initiate a field safety corrective action and notify relevant competent authorities

When PMS data invalidates the benefit-risk profile, the manufacturer must take a field safety corrective action and report it to regulators as required.

Question 90: A sponsor receives an SAE report from an investigator on a Saturday. Under 21 CFR 312.32, fatal unexpected SUSARs must be reported to FDA within:

30 calendar days
15 calendar days
24 hours
7 calendar days (Correct answer)

Correct answer: 7 calendar days

Fatal or life-threatening unexpected serious adverse drug reactions must be reported to the FDA within 7 calendar days.

Question 91: Which regulatory strategy principle is illustrated when a company files for orphan drug designation before beginning Phase 3 trials?

Ensuring the drug is exempt from post-market surveillance
Avoiding the need for clinical trials altogether
Proactive lifecycle planning to secure incentives early in development (Correct answer)
Reactive planning in response to Phase 2 failures

Correct answer: Proactive lifecycle planning to secure incentives early in development

Filing for orphan designation proactively secures benefits including market exclusivity, tax credits, and fee waivers before Phase 3 investment, reflecting forward-looking lifecycle strategy.

Question 92: Which program allows FDA to expedite the development and review of drugs for serious conditions where preliminary evidence shows substantial improvement over available therapies?

Fast Track designation
Accelerated Approval pathway
Priority Review designation
Breakthrough Therapy designation (Correct answer)

Correct answer: Breakthrough Therapy designation

Breakthrough Therapy designation is intended to expedite development of drugs showing preliminary clinical evidence of substantial improvement over existing therapy for serious conditions.

Question 93: A manufacturer of a Class IIb implantable device, which is CE Marked under the EU MDR, must periodically prepare a comprehensive post-market surveillance document for review by their Notified Body. What is this report called?

A Post-Market Surveillance Report (PMSR)
A Medical Device Report (MDR)
An Annual Clinical Evaluation Report (CER)
A Periodic Safety Update Report (PSUR) (Correct answer)

Correct answer: A Periodic Safety Update Report (PSUR)

According to Article 86 of the EU MDR (2017/745), manufacturers of Class IIa, IIb, and III devices must prepare a Periodic Safety Update Report (PSUR). For Class IIb and III devices, this report must be updated at least annually and made available to the Notified Body.

Question 94: A pharmaceutical company is developing a novel drug-eluting stent, a product combining a drug and a device. To formulate an effective regulatory strategy in the United States, what is the MOST critical initial step?

Engaging a contract manufacturing organization that is compliant with both 21 CFR 211 and 21 CFR 820.
Submitting a Request for Designation (RFD) to the Office of Combination Products (OCP) to determine the product's Primary Mode of Action (PMOA). (Correct answer)
Beginning clinical trials immediately to gather efficacy data for both the drug and device components.
Developing separate marketing applications for the drug and device components to streamline the review process.

Correct answer: Submitting a Request for Designation (RFD) to the Office of Combination Products (OCP) to determine the product's Primary Mode of Action (PMOA).

For a combination product like a drug-eluting stent, the most critical first step in regulatory strategy is to determine the Primary Mode of Action (PMOA). The PMOA dictates which FDA center (CDER, CBER, or CDRH) will have primary review jurisdiction. The Office of Combination Products (OCP) is responsible for this assignment. If the PMOA is unclear, a sponsor should submit a Request for Designation (RFD) to the OCP for a formal determination, which is fundamental to defining the entire regulatory pathway.

Question 95: A drug receives Accelerated Approval based on a surrogate endpoint. What post-approval obligation is imposed on the sponsor?

Mandatory REMS program for all patients
Annual re-submission of the NDA
Automatic conversion to Priority Review at renewal
Conducting confirmatory trials to verify clinical benefit (Correct answer)

Correct answer: Conducting confirmatory trials to verify clinical benefit

Under 21 CFR 314.510, Accelerated Approval requires sponsors to conduct post-approval confirmatory studies to verify and describe clinical benefit.

Question 96: What is the primary objective of a regulatory gap analysis performed prior to a global submission strategy?

To determine which markets have no regulatory framework
To calculate the cost of filing fees across jurisdictions
To identify conflicting clinical data between studies
To identify differences in regulatory requirements across target markets that must be addressed in the dossier (Correct answer)

Correct answer: To identify differences in regulatory requirements across target markets that must be addressed in the dossier

A gap analysis compares the existing dossier against the specific requirements of each target market to identify missing data, format issues, or country-specific requirements.

Question 97: When creating a strategic regulatory plan, the process of gathering and analyzing publicly available information on competitor products, regulatory agency decisions, and new guidance documents is known as:

Regulatory intelligence (Correct answer)
Post-market surveillance
Clinical trial monitoring
Marketing research

Correct answer: Regulatory intelligence

Regulatory intelligence is the process of gathering and analyzing publicly available regulatory, scientific, and legal information to inform a company's regulatory strategy. This activity helps a company understand the current regulatory landscape, anticipate changes, learn from competitors' experiences, and make more informed strategic decisions throughout the product lifecycle.

Question 98: Under the Special 510(k) program, what is the primary basis for demonstrating substantial equivalence?

Design controls under 21 CFR Part 820 (Correct answer)
An IDE study
New clinical data
Published performance standards

Correct answer: Design controls under 21 CFR Part 820

The Special 510(k) relies on design controls to demonstrate that device modifications do not affect safety or effectiveness.

Question 99: A company receives approval for a New Drug Application (NDA). Several years post-approval, the FDA requires the sponsor to conduct a new clinical trial to assess a newly identified serious risk associated with the drug's long-term use. This type of study is BEST described as a:

Investigator-Initiated Study
Post-Approval Commitment (PMC)
Phase 4 Clinical Trial
Postmarket Requirement (PMR) (Correct answer)

Correct answer: Postmarket Requirement (PMR)

A study that FDA requires a sponsor to conduct after a drug is approved is called a Postmarket Requirement (PMR). The Food and Drug Administration Amendments Act (FDAAA) of 2007 gave the FDA authority to require PMRs to assess known serious risks, signals of serious risk, or to identify unexpected serious risks. A Post-Approval Commitment (PMC) is a study the sponsor agrees to conduct but is not strictly required by law.

Question 100: In regulatory strategic planning, a 'critical path' analysis primarily helps identify:

The most cost-effective regulatory consultants
The optimal clinical study design
Which countries to enter first based on market size
Activities that directly impact the overall project timeline (Correct answer)

Correct answer: Activities that directly impact the overall project timeline

Critical path analysis identifies the sequence of dependent activities that determine the minimum time required to complete a project.

RAC Regulatory Affairs Certification Exam

The RAC exam, administered by RAPS, certifies regulatory affairs professionals in their knowledge of strategic planning, pre-marketing, post-marketing, and interfacing with regulatory authorities for drugs and devices.

100

Questions

120 min

Time Limit

75%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds

These practice questions were written with AI tools. They are not real exam questions. Exam facts are checked against the official sources listed below. Not reviewed by a subject-matter expert. Editorial policy

Sources & references

Exam facts on this page (fees, format, dates, passing scores) are checked against these official sources; the date is our last check. Editorial policy

raps.org — Fees, score release, exam format, passing score, retake fee, retake policy, renewal, score validity · verified Nov 2026
pearsonvue.com — Test delivery, late registration, registration deadline, test dates · verified Nov 2026